Peroxisomal Impairment in Niemann-Pick Type C Disease*

(Received for publication, May 8, 1996, and in revised form, October 9, 1996)

Sophia Schedin Dagger §, Pavel J. Sindelar , Peter Pentchev par , Ulf Brunk ** and Gustav Dallner Dagger

From the Dagger  Department of Biochemistry, Stockholm University, S-106 91 Stockholm, the  Clinical Research Center, Novum, Karolinska Institutet, S-141 86 Huddinge, and the ** Department of Pathology, University of Linköping, S-581 85 Linköping, Sweden and the par  NINDS, National Institutes of Health, Bethesda, Maryland 20892

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES


ABSTRACT

Niemann-Pick type C disease (NPC) belongs to the group of lysosomal storage diseases characterized by an accumulation of cholesterol and sphingomyelin. Using a mutant mouse strain, enzymatic markers for lysosomes, mitochondria, microsomes, and peroxisomes were investigated in the liver and brain. Aside from lysosomal changes, we found a sizable decrease of peroxisomal beta -oxidation of fatty acids and catalase activity in the brain and liver. Isolated peroxisomes displayed a significant decrease of these enzyme activities. Furthermore, the only phospholipid change in brain was a decreased content of the plasmalogen form of phosphatidylethanolamine, and the dimethylacetal pattern was also modified. The electron microscopical appearance of peroxisomes did not display any large changes. The defect of peroxisomal enzymes was already present 18 days before the onset of the disease. In contrast, the lysosomal marker enzyme increased in activity only 6 days after appearance of the symptoms. The events of the studied process have previously been considered to be elicited by a lysosomal deficiency, but this study demonstrates disturbances similar to those in a number of peroxisomal diseases. It appears that the peroxisomal impairment is an early event in the process and could be a factor in the development of Niemann-Pick type C disease.


INTRODUCTION

Niemann-Pick type C disease is characterized by the accumulation of sphingomyelin and cholesterol in the lysosomes of several organs (1). The genetic defect responsible for this disease is not yet known, but the gene has been localized to chromosome 18 (2). The accumulation of sphingomyelin is considered to be an event secondary to the malfunction of cholesterol transport from the lysosomes to the cytoplasm. Experiments on human fibroblasts from these patients have demonstrated that the endocytosed low density lipoprotein cholesterol is not discharged from the lysosomes and therefore attenuated down-regulation of the key enzyme of cholesterol synthesis, hydroxymethylglutaryl-CoA reductase, occurs (3). Using a mutant mouse model of this disease, it was found that other mevalonate pathway lipids are also affected (4). The concentration of dolichyl phosphate is greatly increased in all organs, and the dolichol transport from the endoplasmic reticulum to the lysosomes is inhibited. There is also a relative increase of the higher isoprene number species of both the dolichol and dolichyl phosphate fractions.

Not only are the contents of the mevalonate pathway lipids and sphingomyelin modified in the disease, several other lipids are also changed, particularly in the liver. Bis(monoacylglycerol)phosphate, glycosylceramide, and sphingoid bases are reported to be elevated (5-7). In the brain, abnormalities are more restricted and mainly affect glycolipids. A severalfold increase of glucosylceramide and lactosylceramide and an increase of GM21 and GM3 gangliosides have been found. In the liver of mutant mice the amount of sterol carrier protein 2, a protein suggested to be involved in cholesterol transport and biosynthesis, is decreased by 80% (8). Most of the various lipid accumulations have been associated with lysosomes, and the levels of several lysosomal enzymes were found to be altered (9).

The extensive modifications in cholesterol and dolichol metabolism and transport raise several questions concerning the biochemical etiology of this disease. These two lipids are synthesized not only in microsomes but also in peroxisomes and are subjected to independent regulations (10-12). In this study, we have therefore investigated the possibility that peroxisomes are also modified in Niemann-Pick type C disease, which is generally considered to be elicited by an enhanced lysosomal storage of lipids. The analyses led to the novel finding that in this condition, in contrast to the lysosomal disorders, a deficiency of peroxisomal function is an early event.


MATERIALS AND METHODS

Animals

In all experiments, a mutant BALB/c mouse model of NPC was used. The parental strain, from which the mutant mice were derived, served as a control. The controls were age-matched to the diseased mice. Since NPC is an autosomal recessively inherited disease, only 25% of the mice develop pathological symptoms. The most prominent symptom is ataxia, which appears around 48-50 days of age. The mice showing ataxia were selected for investigation within 3 days.

Preparation of Homogenate and Subfractionation

After decapitation, tissues were quickly removed and homogenized in 0.25 M cold sucrose (1 g/10 ml) with an ultraturrax blender at 20,000 rpm for 1 min, which effectively disrupts all tissues. This homogenate was centrifuged at 310 × g for 10 min. The supernatant was centrifuged at 2800 × g for 15 min to obtain the heavy mitochondrial/lysosomal fraction (13). The resulting supernatant was centrifuged at 25,300 × g for 15 min, and the pellet was called the light mitochondrial/lysosomal fraction. The supernatant above the latter pellet was centrifuged at 105,000 × g for 60 min to obtain the microsomal fraction.

Mouse liver peroxisomes were isolated on a Nycodenz gradient as described previously (14).

Enzyme Assays

Peroxisomal fatty acyl-CoA oxidase activity was determined using lauroyl-CoA, palmitoyl-CoA, or arachidonyl-CoA as substrates. The H2O2 produced was quantified fluorometrically by following the horseradish peroxidase-catalyzed oxidation of 4-hydroxyphenyl acetic acid into 6,6'-dihydroxy-(1,1'-biphenyl)-3,3'-diacetic acid (15). Palmitoyl-CoA oxidation was monitored by following the reduction of NAD spectrophotometrically at 340 nm. KCN was used to inhibit mitochondrial beta -oxidation (16). Catalase activity in the liver was measured spectrophotometrically at 240 nm by following the disappearance of H2O2 (17). Another catalase assay with higher sensitivity was used for brain samples. After incubation, the remaining H2O2 was quantified by adding titanium oxide sulfate, and the yellow peroxytitanium sulfate complex was measured at 405 nm (18). Urate oxidase was measured by following the oxidation of urate as a decrease in absorbance at 292 nm (18). Cytochrome oxidase and NADPH-cytochrome c reductase were determined as described earlier (18, 19). Acid phosphatase was measured spectrophotometrically at 400 nm, by determining the Na-K-tartrate-inhibited cleavage of p-nitrophenyl phosphate into p-nitrophenol (20).

The protein content was determined according to the method of Lowry et al. (21) with bovine serum albumin as the standard.

Lipid Extraction and Phospholipid Analysis

Chloroform/methanol/water in a ratio of 1:1:0.3 (v/v) was used for the extraction of lipids from tissue homogenates. The pelleted residue was re-extracted with chloroform/methanol (2:1, v/v), and the two supernatants were pooled and the non-lipid residue was used for DNA quantification according to Burton (22). The lipid extract was placed onto a Silica-SepPak cartridge, and the neutral lipids were eluted with chloroform and phospholipids with methanol. All major phospholipid classes were separated by high performance liquid chromatography (HPLC) (23). The phospholipid fraction was dissolved in hexane/2-propanol (3:2, v/v) and injected onto a Zorbax SIL (25 cm × 4.6 mm inner diameter, 5-6 µm) column maintained at 34 °C. Solvent A was hexane/2-propanol (3:2, v/v), and solvent B was hexane/2-propanol/water (56.7:37.8:5.5, v/v). The flow rate was 1.5 ml/min, and the absorbance of the eluant was monitored at 205 nm. The different phospholipid classes were collected and quantified by measuring lipid phosphorus as described previously (24).

The diacyl, alkenylacyl, and alkylacyl subclasses of PE were separated by HPLC after their conversion to 1,2-diradylglycerol derivatives, as described previously (25). The polar head group was removed with phospholipase C (Bacillus cereus, Sigma), and the 1,2-diradylglycerol mixture obtained was acetylated with pyridine and acetic anhydride. Separation of the acetyl diradylglycerol subclasses was achieved on a Zorbax SIL (25 cm × 4.6 mm inner diameter, 5-6 µm) column by an isocratic system consisting of cyclopentane/hexane/t-butylmethyl ether/acetic acid (73:24:2:0.01, v/v). The column was maintained at 36 °C, and the flow rate was 1.5 ml/min. The quantities of alkenylacyl, alkylacyl, and diacyl subclasses were determined by gas chromatography of the fatty acid methyl esters, using heptadecanoic acid as an internal standard.

Fatty Acids and Aldehydes

Lipids were methylated in 14% boron trifluoride in methanol (26), and the resultant fatty acyl methyl esters and dimethyl acetals were extracted with n-pentane/5 M NaOH (4:1, v/v). The upper pentane phase was analyzed by GC on a Shimadzu GC-9A (Kyoto, Japan) equipped with a flame ionization detector. Hydrogen was used as the carrier gas, and the column was a fused silica capillary with a 0.18-µm cyanosiloxane 60 film as the stationary phase (30 m × 0.25 mm inner diameter). The temperature was programmed from 130 °C to 190 °C, and total time per run was 45 min. Fatty acyl methyl esters and dimethyl acetals were identified by comparison of their retention times with known standards. Quantification was achieved by integrating the peaks on a Shimadzu Chromatopac C-R3A.

Electron Microscopy

For electron microscopy, peroxisomes were stained with 3,3'-diaminobenzidine (27). The samples were fixed in a mixture containing 3% glutaraldehyde, 0.2 M sodium cacodylate chloride, and 0.25 M sucrose (pH 7.2) at 4 °C overnight. Postfixation was performed in 1% osmium tetroxide in 0.15 M sodium cacodylate chloride, pH 7.2, for 90 min at 20 °C. The fixed samples were dehydrated and embedded in epoxy resin.


RESULTS

Enzyme Composition

Several enzyme activities, known to be associated with specific organelles, were analyzed in the liver homogenates of mice exhibiting clinical signs of NPC disease, i.e. in the initial phase, around 48-50 days of life. The specific activity of NADPH-cytochrome c reductase, an enzyme present only in the endoplasmic reticulum, was identical in diseased mice and the age-matched controls (Table I). The activity of cytochrome oxidase, a component of the inner mitochondrial membrane, was also unaltered. On the other hand, three enzymes associated with peroxisomes exhibited reduced activity in comparison with the controls. There was a moderate decrease of urate oxidase and catalase activities (20-30%), and the beta -oxidation enzyme, lauroyl-CoA oxidase, activity was decreased by 50%.

Table I.

Enzyme activities in liver homogenate

The homogenates were prepared 2 days after appearance of the symptoms. NADPH-cytochrome c reductase was determined as a microsomal marker; cytochrome oxidase was employed as a marker for the mitochondria; and urate oxidase, catalase, and lauroyl-CoA oxidase were the peroxisomal markers. The values are the means ± S.D. of four separate experiments, using individual mice. *, p < 0.05 ***, p < 0.001.
Enzyme Liver
Control NPC

NADPH-cytochrome c reductasea 3.31  ± 0.41 3.37  ± 0.33
Cytochrome oxidaseb 0.133  ± 0.015 0.154  ± 0.016
Urate oxidasec 0.070  ± 0.005 0.057  ± 0.006*
Catalased 0.406  ± 0.055 0.297  ± 0.028*
Lauroyl-CoA oxidasee 0.891  ± 0.120 0.437  ± 0.028***

a nmol cytochrome c reduced/(min × mg protein).
b µmol cytochrome c oxidized/(min × mg protein).
c µmol urate/(min × mg protein).
d mmol H2O2/(min × mg protein).
e nmol/(min × mg protein).

Differential centrifugation was performed to obtain a heavy mitochondrial/lysosomal fraction and a light mitochondrial/lysosomal fraction, as well as microsomes. The mitochondrial fractions contained the peroxisomes. The peroxisomes present in the two fractions exhibited different properties (Table II). The specific activities of both catalase and lauroyl-CoA oxidase were greatly decreased in the heavy mitochondrial fraction of the diseased mice, while the decrease was quite limited in the light mitochondrial fraction. The specific activity of acid phosphatase was doubled in the two mitochondrial fractions from diseased mice, which is in agreement with the finding that lysosomes are affected in NPC disease. There was also a 3-fold increase of acid phosphatase activity in the microsomes, which may be explained by the slow sedimentation of a fraction of lipid-filled lysosomal vesicles remaining in the microsomal fraction. Both cytochrome oxidase and NADPH-cytochrome c reductase activity remained constant when compared to control mice, indicating that neither the mitochondria nor the endoplasmic reticulum are affected by the disease.

Table II.

Enzyme activities in subfractions of the liver

In each experiment, 4-6 livers from NPC mice, 9-11 days after appearance of the symptoms, were homogenized and fractionated as described under "Materials and Methods." The values are the means ± S.D. of four separate experiments. Each experimental group consisted of 4 mice. *, p < 0.05; ***, p < 0.001. ND, not determined.
Enzyme Heavy mit/lysosomes Light mit/lysosomes Microsomes

Catalasea
  Control 0.630  ± 0.039 0.228  ± 0.025 ND
  NPC 0.328  ± 0.041* 0.204  ± 0.030 ND
Lauroyl-CoA oxidaseb
  Control 9.47  ± 0.35 5.65  ± 0.22 0.13  ± 0.020
  NPC 6.71  ± 0.17*** 5.12  ± 0.45 0.16  ± 0.033
Acid phosphatasec
  Control 31.6  ± 3.8 28.1  ± 4.2 7.77  ± 1.9
  NPC 55.9  ± 7.4*** 59.7  ± 4.1*** 22.8  ± 3.2***
Cytochrome oxidased
  Control 1.10  ± 0.18 0.22  ± 0.021 0.05  ± 0.0016
  NPC 0.99  ± 0.099 0.25  ± 0.033 0.05  ± 0.0050
NADPH-cytochrome c reductasee
  Control 7.59  ± 0.99 6.91  ± 0.55 24.7  ± 2.3
  NPC 5.02  ± 1.05* 7.38  ± 1.1 24.7  ± 1.9

a mmol H2O2/(min × mg protein).
b nmol/(min × mg protein).
c nmol Pi/(min × mg protein).
d µmol cytochrome c oxidized/(min × mg protein).
e nmol cytochrome c reduced/(min × mg protein).

In order to verify the defects at the organelle level, peroxisomes were isolated using Nycodenz gradients (Table III). Using this procedure, the fraction obtained has a very low cross-contamination with other organelles but the recovery is low and prevents extensive investigation. The isolated peroxisomes exhibited 40-50% decreased urate oxidase, catalase, and lauroyl-CoA oxidase activities when the isolated fractions from NPC mice were compared to the control.

Table III.

Specific activities of various enzymes in isolated peroxisomes

Liver peroxisomes were isolated by using Nycodenz gradients. The age of both control and NPC mice were 50-52 days. The values are the means of three individual experiments, using homogenates of 6 livers as starting material.
Enzyme Peroxisomes
Control NPC

Urate oxidasea 0.532 0.352
Catalaseb 2.46 1.55
Lauroyl-CoA oxidasec 41.3 21.5

a µmol urate(min × mg protein).
b mmol H2O2/(min × mg protein).
c nmol H2O2/(min × mg protein).

Brain homogenates were also analyzed for peroxisomal activities. Catalase activity, also in this tissue, was found to be decreased (Table IV). Since brain peroxisomes preferentially oxidize long chain fatty acids, arachidonyl-CoA oxidase was measured and was found to be decreased by as much as 70% in diseased animals.

Table IV.

Peroxisomal enzymes in brain homogenate

The brain was taken for homogenization and enzymatic analysis 2-3 days after the appearance of ataxia. The values are the means of four individual experiments (±S.D.). *, p < 0.05; ***, p < 0.001. 
Enzyme Brain
Control NPC

Catalasea 0.275  ± 0.006 0.189  ± 0.029*
Arachidonyl-CoA oxidaseb 7.76  ± 0.62 2.17  ± 0.32***

a µmol H2O2/(min × mg protein).
b nmol/(min × 100 mg protein).

Peroxisomal Oxidation of Various FA

The peroxisomal beta -oxidation of FA in the liver homogenates was determined by measuring H2O2 production in the presence of various FA-CoA species (Fig. 1). The acyl-CoA oxidase activity measured with octanoyl-, lauroyl-, myristoyl-, palmitoyl-, and arachidonyl-CoA as substrates was decreased by half or more as compared to the control, indicating a generalized impairment of peroxisomal beta -oxidation.


Fig. 1. Fatty acyl-CoA oxidases in liver homogenates of NPC mice. Diseased mice were taken 1-2 days after the appearance of the symptoms for preparation of liver homogenates. Oxidation of octanoyl-, lauroyl-, myristoyl-, palmitoyl-, and arachidonyl-CoA was measured in both NPC mice and age-matched control liver homogenates. The values are the means of separate experiments, using 5 individual mice from each group; the bars show S.D.
[View Larger Version of this Image (20K GIF file)]


Developmental Changes

Symptoms of the disease become apparent around 48 days of age, and the mice die at around 70 days. The peroxisomal and lysosomal activities in the liver were followed during the time period after development of clinical symptoms. When the symptoms first appeared, palmitoyl-CoA oxidation and lauroyl-CoA oxidase as well as catalase and urate oxidase activities were greatly diminished, but activities gradually recovered and almost reached the level of control values by the end of the 3rd week (Fig. 2). In contrast, lysosomal acid phosphatase activity was about the same as the control during the first few days and reached maximal amplification 13 days later.


Fig. 2. Peroxisomal and lysosomal enzyme activities in liver homogenates of NPC mice. NPC mice liver homogenates were prepared 1, 6, 13, and 18 days after the appearance of the symptoms, and the activities of the enzymes were determined. Zero values are defined as those of the age-matched control mice, and the percentage alteration from control values of NPC cases are presented. The values are the means of four separate experiments using individual mice; the bars show S.D.
[View Larger Version of this Image (19K GIF file)]


The experiment above suggested that the peroxisomal enzyme activities may already be decreased before the onset of overt clinical symptoms. Groups of mice pooled into affected and nonaffected were selected for analysis of the liver (Table V). The average age of the mice was 31 days, 18 days before the symptoms are expected to appear. Mice exhibiting elevated levels of cholesterol and dolichyl phosphate were considered as homozygous for the NPC mutation. This group of animals exhibited a considerably decreased activity of peroxisomal beta -oxidation, indicating that the peroxisomal deficiency is manifested long before the appearance of the disease symptoms.

Table V.

Properties of NPC mice livers 18 days before the onset of the disease

The mice in this experiment were the 31-day-old offspring from 3 heterozygous carrier pairs. Liver homogenates were prepared for chemical and enzymatic analyses. Those possessing a 3-fold increase of the cholesterol content would develop the disease within 18 days. The values are the means ± S.D. from 4 separate NPC mice and 6 nondiseased mice. **, p < 0.01; ***, p < 0.001.
Control NPC

Protein contenta 0.159  ± 0.020 0.142  ± 0.007
Cholesterol contentb 2.79  ± 0.72 11.7  ± 1.38***
Dolichyl phosphate contentc 5.19  ± 1.41 11.8  ± 2.00***
Lauroyl-CoA oxidased 0.823  ± 0.141 0.472  ± 0.088**

a g/g liver.
b mg/g liver.
c µg/g liver.
d nmol/(min × mg protein).

Electron Microscopy of the Liver Peroxisomes

Hepatocytes contain morphologically well characterized peroxisomes with a rich proteinaceous content in the lumen. We have used a diaminobenzidine staining procedure, which detects peroxisomal catalase as a granular precipitation (data not shown). No obvious differences in appearance and distribution could be observed between control and NPC liver. Investigating a series of images from both control and diseased tissues, we could not see any great differences in the number or size of these organelles.

Phospholipids of the Brain and Liver

The major phospholipid components of the mouse brain, PE and phosphatidylcholine, are present in about equal amounts (Fig. 3A). The brain is also relatively rich in phosphatidylserine and sphingomyelin, while cardiolipin and phosphatidylinositol are smaller components. No clear-cut difference in total amount of phospholipid could be observed between control and NPC mouse brain. On the other hand, after phospholipid class separation there was a small decrease of PE content. PE consists of two main subclasses, the alkenylacyl and the diacyl forms (Fig. 4). The alkylacyl PE, the precursor of the alkenylacyl form, makes up only a few percent of the total. In the diseased brain, the amount of alkenylacyl PE was decreased by one third, while the levels of the two other forms were unchanged. Thus, the decrease of PE in NPC brain is solely caused by a decrease of PE plasmalogen. Some increase of sphingomyelin was also noticed, but this change was not statistically significant.


Fig. 3. Phospholipid composition of the brain and liver. NPC organs were taken from mice 4-6 days after the development of symptoms. Lipids were extracted from brain and liver homogenates, and the phospholipid classes were separated by HPLC on a silica column. Quantification was performed by determining lipid phosphorus. A, phospholipids from brain; B, phospholipids from liver. The values are the means of five separate experiments. The bars show S.D.; **, p < 0.01.
[View Larger Version of this Image (16K GIF file)]



Fig. 4. Subclasses of PE in mouse brain. NPC mice were taken 4-6 days after the appearance of symptoms for preparation of brain homogenates. After isolation of PE, the lipid was hydrolyzed by phospholipase C and acetylated in the presence of pyridine. The alkenylacyl-, alkylacyl-, and diacyl forms were separated on a silica column by HPLC. Quantification was achieved by gas chromotography of the fatty acid methyl esters. The values are the means of separate experiments, using 4 individual mice from each group. The bars show S.D.; **, p < 0.01.
[View Larger Version of this Image (15K GIF file)]


In NPC liver, the total phospholipid level on DNA basis was increased from 12.89 ± 1.23 to 15.71 ± 1.05 mg of phospholipid/mg of DNA. This is explained by the severalfold elevation of the sphingomyelin content (Fig. 3B). The dominating phospholipid, phosphatidylcholine, as well as cardiolipin, phosphatidylinositol, and phosphatidylserine, all remained unchanged.

Fatty Acid Composition

The fatty acid patterns of total lipids in the brain and liver are very different (Table VI). Dimethyl acetals (DMAs) are the aldehyde associated with carbon 1 on the plasmalogens. They are present in the liver in only minute amounts because of the very low level of plasmalogens in this tissue and therefore were not determined. In both organs, the FA composition of total lipids remained completely unchanged in the diseased state. In the brain, DMAs are restricted to a few components, consisting of 16:0, 18:0, and 18:1. There were significant changes in DMA distribution in the case of NPC brain, apparent as an increase of the 16:0 and a decrease of the 18:1 species.

Table VI.

FAME and DMA compositions of total lipids from mouse brain and liver

The total lipid extracts of the brain and liver were treated with boron trifluoride in methanol in order to prepare fatty acyl methyl esters and dimethyl acetals. Separation and quantification of the individual components was achieved by gas chromatography. The values are the means of five experiments, using separate mice. S.D. values of the means were 3-6%. **, p < 0.01. 
Brain
Liver
NPC Control NPC Control

% of total
FAME
  16:0 27.17 24.73 22.07 22.09
  16:1 0.74 1.09 1.11 0.84
  18:0 20.02 19.80 14.32 13.90
  18:1 17.54 19.91 13.73 14.19
  18:2 1.17 0.78 19.06 19.72
  18:3 0.46 0.47
  20:1 1.19 2.05 0.24 0.39
  20:4 10.13 9.25 17.20 15.85
  22:4 2.63 3.14 1.09 0.58
  22:6 19.34 17.15 9.56 10.14
  24:0 0.59 0.93 1.01 0.52
  24:1 0.78 1.20 1.16 1.24
DMA
  16:0 33.01** 28.83
  18:0 42.65 42.66
  18:1 24.33** 28.53

Because of the observed modifications of the DMA pattern, we also analyzed the FA composition of PE subclasses (Table VII). The plasmalogen form was highly enriched in polyunsaturated FA, while the diacyl form was dominated by the 16:0 and 18:0 species. The FA composition of alkenylacyl and diacyl PE was very similar in both control and NPC mice. The DMA composition of the plasmalogen fraction of the PE was, as expected, similar to that found for the total lipids. In the diseased state, 16:0 was elevated, 18:1 decreased, and 18:0 remained unchanged.

Table VII.

FAME and DMA compositions of PE subclasses in mouse brain

After isolation of PE the diacyl, alkenylacyl, and alkylacyl subclasses were separated by HPLC after their conversion to diradylglycerol derivatives. Fatty acyl methyl esters and dimethylacetals were isolated by gas chromatography. Values are the means of five individual experiments; S.D. values of the means were 2-6%. **, p < 0.01.
Alkenylacyl-PE
Alkylacyl-PE
Diacyl-PE
NPC Control NPC Control NPC Control

% of total
FAME
  16:0 4.80 4.44 12.68 13.10 12.94 10.20
  18:0 2.19 2.09 8.99 7.66 34.18 32.92
  18:1 20.32 20.04 38.17 38.38 11.01 13.18
  20:1 5.62 5.49 4.51 4.28 0.82 1.11
  20:4 15.05 14.33 6.06 6.41 11.78 11.57
  22:4 10.41 12.51 8.44 9.07 2.54 2.68
  22:6 41.63 39.80 21.18 21.12 27.36 27.76
DMA
  16:0 34.24** 27.17
  18:0 41.31 42.78
  18:1 24.45** 30.05


DISCUSSION

The C-type Niemann-Pick disease represents a deviation from other forms of NP, since it is dominated by cholesterol accumulation in the lysosomes, caused by a lesion in the intracellular trafficking of endocytosed cholesterol. The murine model of the disease makes possible a detailed study of the enzyme modifications involved. Using this system, we have found impairments in peroxisomal activities, indicating the involvement of this organelle in the pathogenesis of this disorder. These observations reveal new aspects of the disease process, as they demonstrate that peroxisomal deficiencies occur long before the manifestation of the disease symptoms.

There was a sizable decrease of all peroxisomal enzymes determined in the liver, i.e. beta -oxidation of various types of fatty acids + catalase and urate oxidase. The impairment of beta -oxidation and catalase was also expressed in the brain of these mice, indicating involvement of peroxisomal dysfunction in multiple organs. Furthermore, the only change in brain phospholipids was a 33% decrease of PE plasmalogens. The initial portion of plasmalogen synthesis, formation of the ether bond, takes place in peroxisomes (28), which explains why only plasmalogen and not other phospholipids are affected. The dimethyl acetal pattern of PE plasmalogens was also substantially modified, and, consequently, the decrease in PE plasmalogens is probably caused by an impaired peroxisomal synthesis rather than increased breakdown.

Some peroxisomal diseases, such as Zellweger syndrome, are characterized by accumulation of very long chain fatty acids (29). In these cases, the peroxisomal beta -oxidation is completely missing. In NPC mice, the beta -oxidation is only partially deficient and no changes in the lipid-bound fatty acids could be observed. Thus, it appears that the residual beta -oxidation capacity is sufficient enough, which, together with the relatively short life span of the diseased mice, prevents accumulation of very long chain fatty acids.

Electron microscopical investigations did not reveal great changes in the structure and the number of peroxisomes in the diseased mice. This finding is not surprising since in many identified peroxisomal diseases where partial defects of enzyme systems have been observed, the peroxisomal morphology remained unchanged (30). This fact, however, does not exclude the possibility that structural modifications at the organelle level exist. In our experiments, the peroxisomes present in the heavy mitochondrial fraction displayed considerable enzyme deficiencies in contrast to those present in the light mitochondrial fraction. This suggest that a unique population of this organelle may be responsible for the anomalies found in the disease process.

Isolated peroxisomes exhibit a 40-50% decrease of various peroxisomal enzyme activities, and it would be of considerable interest to perform subfractionation studies to investigate the possible heterogeneity in this fraction. Such a subfractionation study, however, has not yet been performed mainly because of the small number of peroxisomes in the liver and the extremely poor recovery afforded by the present methods employed.

It has previously been found that in the NPC mouse liver, sterol carrier protein-2 exhibits an 80% decrease in the postnuclear fraction (8). This protein is believed to be necessary in certain reactions, including the transformation of lanosterol to cholesterol (31), the activation of the microsomal cis-prenyltransferase (32), and the transport of steroids (33). In the liver, the major part of this protein is present in peroxisomes and the rest is a cytosolic component (34). The large decrease of the level of sterol carrier protein-2 in NPC lends further support to the participation of peroxisomes in the cellular pathogenic events of this disorder.

NPC is associated with a genetic defect on chromosome 18. The nuclear hormone receptor superfamily has a member that is crucial for peroxisome biogenesis, known as the peroxisome proliferator activated receptor, PPAR. PPAR consists of three isoforms, which are activated by distinct signaling pathways and regulated by various other nuclear hormone receptors (35-37). For example, it has been shown that glucocorticoids can stimulate synthesis of PPARalpha mRNA and that this activation was mediated via the glucocorticoid receptor (38). Thus it is plausible that the mutation on chromosome 18 could interfere with peroxisomal activation.

The peroxisomal changes appear not only to be a part of an adaptation mechanism to the disease manifestation but already exist before the appearance of clinical symptoms. During the early phases of clinical presentation, when symptoms like ataxia first appear, peroxisomal enzyme activities are greatly decreased, while lysosomal enzyme markers appear less affected. Surprisingly, all peroxisomal enzyme activities begin to normalize during the late phase of the disease and begin to approach the control values. In contrast, the initially normal acid phosphatase increases continuously and is doubled 2 weeks after the appearance of the symptoms. These results demonstrate that peroxisomal modifications play a significant role in initial events and thereby are important in understanding the etiology of the NPC disease process.


FOOTNOTES

*   This work was supported by grants from the Swedish Medical Research Council and the Swedish Cancer Society.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§   To whom correspondence should be addressed. Tel.: 46-8-162445; Fax: 46-8-153679; E-mail: fia{at}biokemi.su.se.
1   The abbreviations used are: GM2, ceramide-glucose-galactose-(N-acetylneuraminic acid)-N-acetylgalactosamine; GM3, ceramide-glucose-galactose-N-acetylneuraminic acid; NPC, Niemann-Pick type C; FA, fatty acid; PE, phosphatidylethanolamine; DMA, dimethyl acetal; FAME, fatty acyl methyl ester; HPLC, high performance liquid chromatography; PPAR, peroxisome proliferator activated receptor.

REFERENCES

  1. Vanier, M. T., Pentchev, P. G., Rodriguez-Lafrasse, C., and Rousson, R. (1991) J. Inher. Metab. Dis. 14, 580-595 [Medline] [Order article via Infotrieve]
  2. Carstea, E. D., Polymeropoulus, M. H., Parker, C. C., Detera-Wadleigh, S. D., O'Neill, R. R., Patterson, M. C., Goldin, E., Xiao, H., Strauss, R. E., Vanier, M. T., Brady, R. O., and Pentchev, P. G. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2002-2004 [Abstract]
  3. Pentchev, G. G., Brady, R. O., Blanchette-Mackie, E. J., Vanier, M. T., Carstea, E. D., Parker, C. C., Goldin, E., and Roff, C. F. (1994) Biochim. Biophys. Acta 1225, 235-243 [Medline] [Order article via Infotrieve]
  4. Schedin, S., Pentchev, P. G., Brunk, U., and Dallner, G. (1995) J. Neurochem. 65, 670-676 [Medline] [Order article via Infotrieve]
  5. Pentchev, P. G., Vanier, M. T., Suzuki, K., and Patterson, M. C. (1995) in Metabolic and Molecular Basis of Inherited Disease (Scriver, C. R., Beaudet, A. L., Sly, W. S., and Vale, D. D., eds), 7th Ed., pp. 2625-2639, McGraw Hill, New York
  6. Goldin, E., Roff, C. F., Miller, S., Rodriguez-Lafrasse, C., Vanier, M. T., Brady, R. O., and Pentchev, P. G. (1992) Biochim. Biophys. Acta 1127, 303-311 [Medline] [Order article via Infotrieve]
  7. Rodriguez-Lafrasse, C., Rousson, R., Pentchev, P. G., Louisot, P., and Vanier, M. T. (1994) Biochim. Biophys. Acta 1226, 138-144 [Medline] [Order article via Infotrieve]
  8. Roff, C. F., Pastuszyn, A., Strauss, J. F., III, Billheimer, J. T., Vanier, M. T., Brady, R. O., Scallen, T. J., and Pentchev, P. G. (1992) J. Biol. Chem. 267, 15902-15908 [Abstract/Free Full Text]
  9. Pentchev, P. G., Gal, A. E., Booth, A. D., Omodeo-Sale, F., Fouks, J., Neumeyer, B. A., Quirk, J. M., Dawson, G., and Brady, R. O. (1980) Biochim. Biophys. Acta 619, 669-679 [Medline] [Order article via Infotrieve]
  10. Grünler, J., Ericsson, J., and Dallner, G. (1994) Biochim. Biophys. Acta 1212, 259-277 [Medline] [Order article via Infotrieve]
  11. Ericsson, J., Appelkvist, E.-L., Thelin, A., Chojnacki, T., and Dallner, G. (1992) J. Biol. Chem. 267, 18708-18714 [Abstract/Free Full Text]
  12. Ericsson, J., Runquist, M., Thelin, A., Andersson, M., Chojnacki, T., and Dallner, G. (1993) J. Biol. Chem. 268, 832-838 [Abstract/Free Full Text]
  13. Runquist, M., Ericsson, J., Thelin, A., Chojnacki, T., and Dallner, G. (1994) J. Biol. Chem. 269, 5804-5809 [Abstract/Free Full Text]
  14. Appelkvist, E. L., Reinhart, M., Fischer, R., Billheimer, J., and Dallner, G. (1990) Arch. Biochem. Biophys. 282, 318-325 [Medline] [Order article via Infotrieve]
  15. Poosch, M. S., and Yamazaki, R. K. (1986) Biochim. Biophys. Acta 884, 585-593 [Medline] [Order article via Infotrieve]
  16. Lazarow, P. B., and DeDuve, C. (1976) Proc. Natl. Acad. Sci. U. S. A. 78, 2043-2046
  17. Bergmeyer, H. U. (1955) Biochim. Z. 327, 255-258
  18. Leighton, F., Poole, B., Beaufay, H., Baudhuin, P., Coffey, J. W., Fowler, S., and DeDuve, C. (1968) J. Cell Biol. 37, 482-513 [Abstract/Free Full Text]
  19. Sottacosa, G. L., Kuylenstierna, G., Ernster, L., and Bergenstrand, A. (1967) J. Cell Biol. 32, 415-438 [Abstract/Free Full Text]
  20. Ganoza, M. C. (1964) The Role of Lipid in Glucose-6-phosphatase. Ph.D. thesis, Duke University, University Microfilms, Inc., Ann Arbor, MI
  21. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) J. Biol. Chem. 193, 265-275 [Free Full Text]
  22. Burton, K. (1956) Biochem. J. 62, 315-323
  23. Dugan, L. L., Demediuk, P., Pendley, C. E., II, and Horrocks, L. A. (1986) J. Chromatogr. 378, 317-327 [CrossRef][Medline] [Order article via Infotrieve]
  24. Valtersson, C., and Dallner, G. (1982) J. Lipid Res. 23, 868-876 [Abstract/Free Full Text]
  25. Nakagawa, Y., and Horrocks, L. A. (1983) J. Lipid Res. 24, 1268-1275 [Abstract]
  26. Morrison, W. R., and Smith, L. M. (1964) J. Lipid Res. 5, 600-608 [Abstract/Free Full Text]
  27. Angermüller, S., and Fahimi, H. D. (1981) Histochemistry 71, 33-44 [Medline] [Order article via Infotrieve]
  28. van den Bosch, H., Schutgens, R. B. H., Wanders, R. J. A., and Tager, J. M. (1992) Annu. Rev. Biochem. 61, 157-197 [CrossRef][Medline] [Order article via Infotrieve]
  29. Lazarow, P. B., and Moser, H. W. (1989) in Metabolic Basis of Inherited Disease (Scriver, C. R., Beaudet, A. L., Sly, W. S., and Valle, D., eds), 6th Ed., pp. 1479-1509, McGraw Hill, New York
  30. Goldfischer, S. L. (1988) in The Liver: Biology and Pathobiology (Arias, I. M., Jakoby, W. B., Popper, H., Schachter, D., and Shafritz, D. A., eds), 2nd Ed., pp. 255-267, Raven Press, New York
  31. Scallen, T. J., Schuster, M. W., and Dhar, A. K. (1971) J. Biol. Chem. 246, 224-230 [Abstract/Free Full Text]
  32. Ericsson, J., Scallen, T. J., Chojnacki, T., and Dallner, G. (1991) J. Biol. Chem. 266, 10602-10607 [Abstract/Free Full Text]
  33. Scallen, T. J., Pastuszyn, A., Noland, B. J., Roland, C., Kharroubi, A., and Vahouny, G. V. (1985) Chem. Phys. Lipids 38, 239-261 [CrossRef][Medline] [Order article via Infotrieve]
  34. Ossendorp, B. C., and Wirtz, K. W. A. (1993) Biochemie 75, 191-200 [CrossRef][Medline] [Order article via Infotrieve]
  35. Dreyer, C., Krey, G., Keller, H., Givel, F., Helftenbein, G., and Wahli, W. (1992) Cell 68, 879-887 [Medline] [Order article via Infotrieve]
  36. Issemann, I., and Green, S. (1990) Nature 347, 645-649 [CrossRef][Medline] [Order article via Infotrieve]
  37. Keller, H., Dreyer, C., Medin, J., Mahfoudi, A., Ozato, K., and Wahli, W. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2160-2164 [Abstract]
  38. Lemberger, T., Staels, B., Saladin, R., Desvergne, B., Auwerx, J., and Wahli, W. (1994) J. Biol. Chem. 269, 24527-24530 [Abstract/Free Full Text]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.